Back

Convalescence from prototype SARS-CoV-2 protects Syrian hamsters from disease caused by the Omicron variant

Ryan, K. A.; Watson, R. J.; Bewley, K. R.; Burton, C. A.; Carnell, O.; Cavell, B. E.; Challis, A. R.; Coombes, N. S.; Emery, K.; Fell, R.; Fotheringham, S. A.; Gooch, K. E.; Gowan, K.; Handley, A.; Harris, D. J.; Humphreys, R.; Johnson, R.; Knott, D.; Lister, S.; Morley, D.; Ngabo, D.; Osman, K. L.; Paterson, J.; Penn, E. J.; Pullen, S. T.; Richards, K. S.; Shaik, I.; Summers, S.; Thomas, S. R.; Weldon, T.; Wiblin, N. R.; Vipond, R.; Hallis, B.; Funnell, S. G. P.; Hall, Y.

2021-12-26 microbiology
10.1101/2021.12.24.474081 bioRxiv
Show abstract

The mutation profile of the SARS-CoV-2 Omicron variant poses a concern for naturally acquired and vaccine-induced immunity. We investigated the ability of prior infection with an early SARS-CoV-2, 99.99% identical to Wuhan-Hu-1, to protect against disease caused by the Omicron variant. We established that infection with Omicron in naive Syrian hamsters resulted in a less severe disease than a comparable dose of prototype SARS-CoV-2 (Australia/VIC01/2020), with fewer clinical signs and less weight loss. We present data to show that these clinical observations were almost absent in convalescent hamsters challenged with the same dose of Omicron 50 days after an initial infection with Australia/VIC01/2020. The data provide evidence for immunity raised against prototype SARS-CoV-2 being protective against Omicron in the Syrian hamster model. Further investigation is required to conclusively determine whether Omicron is less pathogenic in Syrian hamsters and whether this is predictive of pathogenicity in humans.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.